BIO-NANO-CHIP FOR ANTICONVULSANT DRUG SALIVARY ASSAY

• US 20150111778A1
• Filed: 10/01/2014
• Published: 04/23/2015
• Est. Priority Date: 10/21/2013
• Status: Abandoned Application

• Current Assignee: Rice University, Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Rice University, Board of Regents of the University of Texas System (University of Texas System)
• Inventors: MCDEVITT, John T., CHRISTODOULIDES, Nicolaos, KALAMANGALAM, Giridhar P.
• Application Number:
  US14/503,400
• Publication Number:
  US 20150111778A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: B01L 2200/0668 Trapping microscopic beads
• CPC Class Codes: B01L 2300/0636 Integrated biosensor, microarrays
• CPC Class Codes: B01L 2300/0816 Cards, e.g. flat sample carriers usually with flow in two horizontal directions
• CPC Class Codes: B01L 2300/0819 Microarrays; Biochips
• CPC Class Codes: B01L 2300/0867 Multiple inlets and one sample wells, e.g. mixing, dilution
• CPC Class Codes: B01L 2300/087 Multiple sequential chambers
• CPC Class Codes: B01L 2400/0481 squeezing of channels or chambers
• CPC Class Codes: B01L 3/502761 specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules investigating characteristics of particles G01N15/00
• CPC Class Codes: G01N 2800/2857 Seizure disorders; Epilepsy
• CPC Class Codes: G01N 33/54366 Apparatus specially adapted for solid-phase testing
• CPC Class Codes: G01N 33/9473 Anticonvulsants, e.g. phenobarbitol, phenytoin

Abstract

This disclosure describes portable bio-nano-chip (BNC) assays of antiepileptic drugs (AED) using salivary samples. The BNC technology results in a more convenient, less expensive, and less time consuming sampling and analysis.

Claims

1. A disposable drug testing cartridge comprising a generally flat substrate having thereon individual bead sensors arranged in an array, wherein each said bead sensor is a porous polymeric bead having a drug bound thereto to form a drug bead sensor, wherein said drug is selected from three or more of valproic acid, phenobarbital, phenytoin, clonazepam, carbamazepine, ethosuximide, felbamate, tiagabine, levetiracetam, lamotrigine, pregabalin, gabapentin, topomax, zonisamide, perampanel, lacosamide, topiramate, oxcarbazepine, and biological metabolites or derivatives of same.

2. The disposable drug testing cartridge of claim 1, further comprising internal microfluidics on said substrate for carrying fluid to and from said bead sensors.

3. The disposable drug testing cartridge of claim 2, further comprising a sample entry port.

4. The disposable drug testing cartridge of claim 3, further comprising at least one reagent blister fluidly connected to said bead sensors.

5. The disposable drug testing cartridge of claim 4, further comprising at least one waste fluid chamber fluidly connected to and downstream of said bead sensors.

6. The disposable drug testing cartridge of claim 4, further comprising positive and negative control bead sensors and calibrator bead sensors.

7. The disposable drug testing cartridge of claim 4, wherein every said drug bead sensor is present in said array in at least duplicate.

8. The disposable drug testing cartridge of claim 4, wherein every said drug bead sensor is present in said array in at least triplicate.

9. The disposable drug testing cartridge of claim 4, wherein said drug is conjugated to said bead sensor via a linker.

10. The disposable drug testing cartridge of claim 1, said cartridge further comprising:

a) one or more reagent chambers fluidly connected to and upstream of said array; and

b) one or more waste fluid chambers fluidly connected to and downstream of said array;

c) a sample inlet upstream and fluidly connected to said one or more reagent chambers; and

d) wherein each bead sensor is a porous polymeric bead of size between 50-300 nm ±

10%.

11. An assay for the monitoring of anti-epilepsy drug concentration in saliva, said assay comprising:

a) obtaining a sample of oral fluid from a patient;

b) immunologically testing said sample to determine the level of anti-epileptic drugs; and

c) wherein said testing is conducted on an array of agarose beads, conjugated to anti-epileptic drugs, and wherein signal from said array of agarose beads is analyzed by circular area of interest or line profiling or both.

12. The assay of claim 11, wherein said anti-epileptic drugs are selected from three or more of valproic acid, phenobarbital, phenytoin, clonazepam, carbamazepine, ethosuximide, felbamate, tiagabine, levetiracetam, lamotrigine, pregabalin, gabapentin, topomax, zonisamide, perampanel, lacosamide, topiramate, and oxcarbazepine and biological metabolites of same.

13. An anti-epileptic drug testing assay system comprising:

a) a microfluidic lab-on-chip based reverse competitive immunoassay that comprises a disposable cartridge and a separate reader, wherein said cartridge fits into a slot on said reader, and said reader performs said competitive immunoassay and outputs a result;

b) said cartridge comprising;

i) a generally flat substrate having embedded microfluidic channels connecting an inlet port to an embedded downstream assay chamber having a transparent cover and containing a removable array of bead sensors;

ii) one or more reagent chambers fluidly connected to and upstream of said assay chamber; and

iii) one or more waste fluid chambers fluidly connected to and downstream of said assay chamber;

iv) wherein each bead sensor is a porous polymeric bead of size between 50-300 nm ±

10% having a drug conjugated thereto, wherein said drug is selected from three or more of valproic acid, phenobarbital, phenytoin, clonazepam, carbamazepine, ethosuximide, felbamate, tiagabine, levetiracetam, lamotrigine, pregabalin, gabapentin, topomax, zonisamide, perampanel, lacosamide, topiramate, and oxcarbazepine and biological metabolites or derivatives of same; and

c) wherein said reverse competitive immunoassay has a lower limit of detection for each of said drugs of <

50 ng/ml and a detection range of at least four orders of magnitude.

14. The drug testing assay of claim 13, wherein said cartridge comprising 4 or more of said drugs.

15. The drug testing assay of claim 13, wherein said cartridge comprising each of said drugs.

16. A kit, comprising the cartridge of claim 13 wrapped in an airtight package, a vial of assay fluid, and an oral swab.

17. A anti-epileptic drug home testing assay kit comprising:

a) a microfluidic lab-on-chip based reverse competitive immunoassay that comprises a disposable cartridge;

b) a sample collection and solubilization device comprising;

i) a container closed with a removable cap;

ii) a lower portion of said container having an assay fluid separated from an upper portion of said container by a piercable membrane;

iii) said cap comprising a flexible bulb passing through said cap and fluidly connected to a hollow stem ending in a point, a lower portion of said stem being coated with an absorbent or bristled material for collecting a biological sample;

iv) wherein said device is proportioned to store said cap with said stem and said swab in said upper portion of said container, but can reach said buffer when said point pierces said piercable membrane, and said flexible bulb can be used to draw up and deliver said buffer;

c) said cartridge comprising;

i) a generally flat substrate having embedded microfluidic channels connecting an inlet port to an embedded downstream assay chamber having a transparent cover and containing a removable array of bead sensors;

ii) one or more reagent chambers fluidly connected to and upstream of said assay chamber;

iii) one or more waste fluid chambers fluidly connected to and downstream of said assay chamber; and

iv) wherein each bead sensor is a porous polymeric bead of size between 50-300 nm ±

10% having a drug conjugated thereto, wherein said drug is selected from three or more of valproic acid, phenobarbital, phenytoin, clonazepam, carbamazepine, ethosuximide, felbamate, tiagabine, levetiracetam, lamotrigine, pregabalin, gabapentin, topomax, zonisamide, perampanel, lacosamide, topiramate, and oxcarbazepine and biological metabolites or derivatives of same.